Comparative guide · 6 min read

NMN vs Resveratrol for longevity — what the human evidence actually says

Updated 2026-05-18 · Reviewed by SupplementScore editors · No sponsorships

No supplement on the market has ever been shown to extend healthy human lifespan. Both NMN and resveratrol have generated impressive rodent and cell data on NAD+ metabolism and sirtuin biology, and both ride large marketing budgets and high-profile longevity-clinic adoption. The honest read of the current human data: NMN reliably raises blood NAD+ but the downstream clinical endpoints (insulin sensitivity, aerobic capacity, frailty markers) are modest and not yet replicated at scale; resveratrol bioavailability is poor and human trials are largely negative on the headline endpoints. Neither is a no-brainer — but if you're going to pick one, the pharmacokinetic case for NMN is stronger.

Quick verdict

GoalBetter choiceWhy
Raising measurable blood NAD+NMN (or NR)Multiple RCTs show 1.5–2× NAD+ rise; resveratrol does not raise NAD+ directly.
"Sirtuin activator" rationaleResveratrol (in theory; weak in humans)Sirtuin activation was the original hypothesis; the human data has not borne it out at oral doses.
Cardiovascular endpointsResveratrol (modest BP signal)Small effect on SBP/DBP in some trials; effect size smaller than dietary changes.
Insulin sensitivity / metabolic markersNMNSeveral small RCTs show improvements; effect size modest, sample sizes small.
Frailty / 6-minute walk test in older adultsNMN (preliminary)One small RCT showed improved gait speed; needs replication.
Skeletal muscle NAD+ in elite athletesNMNIncreases tissue NAD+ but performance benefit is unclear.
Regulatory status (in the US, 2025)Resveratrol (clearer)NMN's status as a supplement has been contested by FDA; the regulatory picture remains fluid.

How they compare on the things that matter

Mechanism — NAD+ precursor vs sirtuin activator

NMN (nicotinamide mononucleotide) is a direct precursor in the salvage pathway that produces NAD+, a coenzyme essential for over 500 reactions including those carried out by sirtuins (SIRT1–7), PARPs, and CD38. NAD+ declines with age, and pre-clinical studies suggest raising NAD+ can improve mitochondrial function, DNA repair, and metabolic flexibility. Whether oral NMN reaches all the tissues that need NAD+ remains a live debate — gut conversion to nicotinamide is substantial.

Resveratrol is a stilbenoid polyphenol found in grape skin, red wine, and peanuts. The original "longevity" excitement was based on its in vitro activation of SIRT1. In humans, oral resveratrol is extensively metabolised to sulfate and glucuronide conjugates by the gut and liver, giving very low plasma concentrations of free resveratrol. The clinical effects observed (modest BP, vascular function, insulin sensitivity) may reflect a different mechanism than direct sirtuin activation.

Evidence base by endpoint

Practical rule. Both belong in the "speculative, modest evidence, accept the uncertainty" category. NMN at 500–1000 mg/day has the cleanest pharmacokinetic story (blood NAD+ rises) and the most promising metabolic-endpoint trial signal. Resveratrol at supplement doses (250–500 mg/day) is unlikely to do much on the longevity endpoints it's marketed for because of bioavailability. If you want resveratrol-class effects, dietary patterns rich in polyphenols (berries, olive oil, tea, coffee, dark chocolate) are likely a better delivery vehicle than capsules.

Dose and form

For NMN, trial doses run 250–1000 mg/day, typically as a single morning dose with food. Higher doses (500+ mg) have shown more reliable NAD+ rise. Sublingual or liposomal claims of "superior absorption" lack head-to-head trial comparison. Storage stability matters — some products degrade rapidly at room temperature.

For resveratrol, trans-resveratrol is the active form. Typical supplement doses are 250–500 mg/day. Taking with fat improves absorption modestly. Pterostilbene (a methylated analogue) has better bioavailability and is sometimes pitched as an upgrade — see the dedicated resveratrol-vs-pterostilbene page.

Safety

NMN has been well-tolerated in trials up to 1200 mg/day for 60 days. Long-term safety data are limited. There is theoretical concern about whether sustained NAD+ elevation could affect tumour-cell metabolism (some cancers are NAD+-avid); this is unresolved.

Resveratrol at supplement doses is generally well-tolerated. Cautions include CYP3A4 inhibition (raises blood levels of several drugs), antiplatelet effect (additive bleeding risk with anticoagulants), and oestrogen-receptor activity at higher doses. Discontinue at least 2 weeks before scheduled surgery.

What the price difference buys you

NMN at 500–1000 mg/day runs $1.50–4.00/day — by far the more expensive option. Resveratrol at 250–500 mg/day runs $0.30–0.80/day. Per dollar, neither has compelling outcome data; per dollar of demonstrated mechanism (NAD+ rise), NMN has the cleaner story but you're paying for it.

Who should skip each

NMN should be approached cautiously in active malignancy (theoretical NAD+/cancer-metabolism concern), in pregnancy and breastfeeding (no safety data), and in users with kidney impairment.

Resveratrol should be approached cautiously in users on anticoagulants, antiplatelets, or CYP3A4-metabolised drugs (statins, tacrolimus, cyclosporine). Discontinue at least 2 weeks before surgery. Hormone-sensitive conditions warrant caution at higher doses.

What we'd actually buy

If you have the budget and the comfort with uncertainty, NMN 500–1000 mg/day in the morning for an experiment that includes baseline and follow-up biomarkers (HbA1c, fasting insulin, lipids, blood pressure, grip strength, 6-minute walk if you can measure it). Set a 12-month decision rule — if your tracked endpoints haven't moved, stop.

For resveratrol, we'd put the budget into dietary polyphenols (berries daily, olive oil as the dominant cooking fat, tea or coffee, dark chocolate, walnuts) before the supplement. If you want the supplement anyway, 250–500 mg/day with a fat-containing meal — but expect modest effects.

Sources

Read more: